NCT01447251View on ClinicalTrials.gov

Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Obstructive Sleep ApneaDiabetes Mellitus
Interventions
BEHAVIORAL

PreDx Diabetes Risk Score

The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS \<4.5, moderate risk as PreDx DRS ≥4.5 and \<8.0, and high risk as PreDx DRS ≥8.0.

Trial Locations (1)

89191

Mike O'Callaghan Federal Hospital/Nellis AFB, Las Vegas

All Listed Sponsors
lead

Mike O'Callaghan Military Hospital

FED

NCT01447251 - Assessing the Risk of Developing Type II Diabetes Using Serum Biomarkers in Patients Diagnosed With Obstructive Sleep Apnea | Biotech Hunter | Biotech Hunter